Instadose Pharma Corp. (OTC MKTS: INSD) in January 2022 will address the conference, Future Cannabis Strategies Europe, held in London on the ‘Future Of Medicinal Cannabis’. The company will focus on the growing global role of medicinal cannabis and its impact on developing nations. It will discuss its benefits and potential impact on emerging nations.
INSD will be a knowledgeable speaker on the subject due to its Global Distribution Platform. This is a program that spans five continents to date. This includes North America, South America, Asia, Africa and Europe.
INSD stock is on a tear. In September it was $5 a share. It closed last evening at $27.00, up 2.08% in heavy volume of 5,998. Before its reverse merger on September 24, it was a shell company with no operations.
INSD Chairman Grant Sanders said, “The commoditization of Cannabis will have a huge impact on countries where it can be grown outdoors, particularly in the developing world. The hope is that these countries will benefit from the development of a global market for Medicinal Cannabis.
“Food and water security, as well as, the environment and climate change, are global issues and Medicinal Cannabis could be central to the story as a green renewable resource,” he concluded.
Instadose Pharma Corp. Canada had attended a similar virtual conference in August. Titled “Future Cannabis Strategies North America,” executives spoke on the subject of “Evergreen Everlasting.”
INSD has operational subsidiaries and joint partnerships to help secure access to government-issued licenses and permits. It has established them in:
- The Democratic Republic of the Congo (DRC)
- Republic of India
- Columbia, Mexico
- Republic of North Macedonia
- Portuguese Republic
INSD said its relationships with international partners are based on sustainable and long-term agreements. The goal is to protect the natural environment and give back to people. Instadose projects aim to increase quality of life, offer fresh water, education, food, security, capital and jobs.
Recently, Instadose Pharma Corp. Canada announced it was establishing a second European import location in Portugal. This is in addition to its import location in North Macedonia. It will represent Instadose Pharma Corp. Canada’s first EU based location to serve the Company’s Global Distribution Platform.
Instadose Pharma Corp. (OTC MKTS: INSD) is seeking to create a large, outdoor growing, cultivation and global distribution program for its Medicinal Cannabis and Cannabinoid Oil. It would, through its Global Distribution Platform, gain global access to a new wholesale market worldwide.
This wholesale marketplace would then offer low-cost product as a bulk and active pharmaceutical ingredient. It would be large, sustainable, consistent, diverse and high quality.
Instadose Canada recently signed strategic joint partnerships and supply agreement with JV partners in Columbia to export medical cannabis to Europe through INSD’s Global Distribution Platform
It has also completed supply agreements with its Columbia JV Partners for the shipment of 100,000 kg of medical cannabis to Instadose’s facility in North Macedonia in Q1 of 2022.
Grant Sanders, Chairman of Instadose, said, “Our Columbia joint ventures are strategic in that it enhances our Global Distribution Platform with (some of) the highest quality and sought-after product in the world.”
The global medicinal cannabis market is anticipated to reach $46.18 billion by 2026 at a CAGR of 22.9% from 2021, according to research by Market Data Forecast.
The company operates a total of 40,000+ hectares of outdoor growing space in Southern Africa, Mexico and DRC. This combined area is larger than that of its top three competitors combined, the company reports.